BIOFRONTERA AG/ADR (NASDAQ:BFRA) had its price objective boosted by Lake Street Capital from $19.00 to $24.00 in a research note published on Tuesday morning, The Fly reports. The brokerage currently has a buy rating on the stock.
Separately, Benchmark reaffirmed a buy rating on shares of BIOFRONTERA AG/ADR in a research report on Tuesday, March 26th.
NASDAQ:BFRA opened at $14.38 on Tuesday. The stock has a market cap of $318.13 million, a PE ratio of -30.60 and a beta of 1.09. BIOFRONTERA AG/ADR has a 1 year low of $11.04 and a 1 year high of $16.06. The company has a quick ratio of 5.58, a current ratio of 6.28 and a debt-to-equity ratio of 1.02.
BIOFRONTERA AG/ADR Company Profile
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.
Further Reading: What is a Fiduciary?
Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.